CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Kineret anakinra Still's disease Withdrawn
Aduhelm aducanumab Alzheimer’s disease Withdrawn
Keytruda and Lenvima pembrolizumab and lenvatinib Advanced endometrial cancer Withdrawn
TBC risperidone Schizophrenia, adults Suspended
Prevymis letermovir Cytomegalovirus infection (CMV), prophylaxis Withdrawn
Ebglyss lebrikizumab atopic dermatitis Active
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Suspended
TBC exagamglogene autotemcel Transfusion-dependent β-thalassemia Active
N/A imiquimod Gynecological cancers Withdrawn
Ultomiris ravulizumab Generalized Myasthenia Gravis Active
Vabysmo faricimab Retinal vein occlusion Active
Spevigo spesolimab generalized pustular psoriasis (GPP) Active
Leqembi lecanemab Alzheimer’s disease Active
Vanflyta quizartinib acute myeloid leukemia (AML) Pending
N/A Enzalutamide Genito-urinary cancer (prostate cancer) Active
Balversa erdafitinib locally advanced unresectable or metastatic urothelial carcinoma (UC) Active
TBC momelotinib Myelofibrosis Active
Rybrevant amivantamab Locally advanced or metastatic non-small cell lung cancer (NSCLC) Active
Ryaltris olopatadine hydrochloride and mometasone Seasonal allergic rhinitis Active
TBC zolbetuximab Gastric or gastroesophageal junction (GEJ) adenocarcinoma Active
N/A nab-paclitaxel Gastrointestinal cancer Active
Isturisa osilodrostat Endogenous Cushing’s syndrome Suspended
N/A everolimus Tuberous Sclerosis Complex (TSC) Active
Zilbrysq zilucoplan Generalized myasthenia gravis (gMG) Active
Tafinlar-Mekinist dabrafenib trametinib Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation Pending
Last Updated : September 8, 2024